Antidepressant-like effect of atorvastatin in the forced swimming test in mice: The role of PPAR-gamma receptor and nitric oxide pathway

European Journal of Pharmacology

Volumn 745, Issue , 2014, Pages 52-58

  Shahsavarian, Arash ^a   Javadi, Shiva ^b   Jahanabadi, Samane ^b,c   Khoshnoodi, Mina ^b   Shamsaee, Javad ^b   Shafaroodi, Hamed ^a   Mehr, Shahram Ejtemaei ^b,d   Dehpour, Ahmadreza ^b,c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atorvastatin; Depression; FST; Mice; Nitric oxide; Pioglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ANTIDEPRESSANT AGENT; ARGININE; ATORVASTATIN; IMIPRAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; FORCED SWIM TEST; INCIDENCE; LIPOPHILICITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; SIGNAL TRANSDUCTION; SWIMMING;

ANILIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMIPRAMINE; MALE; MICE; MOTOR ACTIVITY; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PPAR GAMMA; PYRROLES; SIGNAL TRANSDUCTION; SWIMMING; THIAZOLIDINEDIONES;

EID: 84919336601     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.10.004     Document Type: Article

References (42)

1. M. Aihara, I. Ida, N. Yuuki, A. Oshima, H. Kumano, K. Takahashi, M. Fukuda, N. Oriuchi, K. Endo, H. Matsuda, and M. Mikuni HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions Psychiatry Res. 155 3 2007 245 256
2. C. Bell, J. Abrams, and D. Nutt Tryptophan depletion and its implications for psychiatry Br. J. Psychiatry 178 2001 399 405
3. O. Berton, and E.J. Nestler New approaches to antidepressant drug discovery: beyond monoamines Nat. Rev. Neurosci. 7 2 2006 137 151
4. E. Boumendil, and P. Tubert-Bitter Depression-induced absenteeism in relation to antihyperlipidemic treatment: a study using GAZEL cohort data Epidemiology 6 3 1995 322 325
5. J. Brunner, K.G. Parhofer, P. Schwandt, and T. Bronisch Cholesterol, essential fatty acids, and suicide Pharmacopsychiatry 35 1 2002 1 5
6. R. Corti, J.I. Osende, J.T. Fallon, V. Fuster, G. Mizsei, H. Jneid, S.D. Wright, W.F. Chaplin, and J.J. Badimon The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging J. Am. Coll. Cardiol. 43 3 2004 464 473
7. G.D. da Silva, A.S. Matteussi, A.R. dos Santos, J.B. Calixto, and A.L. Rodrigues Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice Neuroreport 11 17 2000 3699 3702
8. J.V. Esplugues NO as a signalling molecule in the nervous system Br. J. Pharmacol. 135 5 2002 1079 1095
9. D.L. Feinstein, E. Galea, V. Gavrilyuk, C.F. Brosnan, C.C. Whitacre, L. Dumitrescu-Ozimek, G.E. Landreth, H.A. Pershadsingh, G. Weinberg, and M.T. Heneka Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis Ann. Neurol. 51 6 2002 694 702
10. J.D. Fernstrom, and R.J. Wurtman Brain serotonin content: increase following ingestion of carbohydrate diet Science 174 4013 1971 1023 1025
11. M. Ghasemi, H. Sadeghipour, A. Mosleh, H.R. Sadeghipour, A.R. Mani, and A.R. Dehpour Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test Eur. Neuropsychopharmacol. 18 5 2008 323 332
12. A. Harkin, T.J. Connor, M.P. Burns, and J.P. Kelly Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test Eur. Neuropsychopharmacol. 14 4 2004 274 281
13. A.J. Harkin, K.H. Bruce, B. Craft, and I.A. Paul Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test Eur. J. Pharmacol. 372 3 1999 207 213
14. M.T. Heneka, G.E. Landreth, and M. Hull Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders Nat. Clin. Pract. Neurol. 3 9 2007 496 504
15. M.T. Heneka, M. Sastre, L. Dumitrescu-Ozimek, A. Hanke, I. Dewachter, C. Kuiperi, K. O'Banion, T. Klockgether, F. Van Leuven, and G.E. Landreth Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice Brain 128 Pt 6 2005 1442 1453
16. S.Y. Inan, I. Yalcin, and F. Aksu Dual effects of nitric oxide in the mouse forced swimming test: possible contribution of nitric oxide-mediated serotonin release and potassium channel modulation Pharmacol. Biochem. Behav. 77 3 2004 457 464
17. N.C. Inestrosa, J.A. Godoy, R.A. Quintanilla, C.S. Koenig, and M. Bronfman Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling Exp. Cell Res. 304 1 2005 91 104
18. I. Inoue, S. Goto, K. Mizotani, T. Awata, T. Mastunaga, S. Kawai, T. Nakajima, S. Hokari, T. Komoda, and S. Katayama Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells Life Sci. 67 8 2000 863 876
19. D. Jefferys, and J. Funder Nitric oxide modulates retention of immobility in the forced swimming test in rats Eur. J. Pharmacol. 295 2-3 1996 131 135
20. D.E. Kemp, F. Ismail-Beigi, and J.R. Calabrese Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome Am. J. Psychiatry 166 5 2009 619
21. J.K. Kiecolt-Glaser, and R. Glaser Depression and immune function: central pathways to morbidity and mortality J. Psychosom. Res. 53 4 2002 873 876
22. J.Z. Konarski, R.S. McIntyre, S.H. Kennedy, S. Rafi-Tari, J.K. Soczynska, and T.A. Ketter Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder Bipolar Disord. 10 1 2008 1 37
23. M. Ledochowski, C. Murr, B. Sperner-Unterweger, G. Neurauter, and D. Fuchs Association between increased serum cholesterol and signs of depressive mood Clin. Chem. Lab. Med. 41 6 2003 821 824
24. D. Lu, A. Mahmood, C. Qu, A. Goussev, M. Lu, and M. Chopp Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact J. Neurosurg. 101 5 2004 822 825
25. F.K. Ludka, A.D. Zomkowski, M.P. Cunha, T. Dal-Cim, A.L. Zeni, A.L. Rodrigues, and C.I. Tasca Acute atorvastatin treatment exerts antidepressant-like effect in mice via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels Eur. Neuropsychopharmacol. 23 5 2013 400 412
26. S. Moncada, R.M. Palmer, and E.A. Higgs Nitric oxide: physiology, pathophysiology, and pharmacology Pharmacol. Rev. 43 2 1991 109 142
27. S. Moreno, S. Farioli-Vecchioli, and M.P. Ceru Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS Neuroscience 123 1 2004 131 145
28. M. Nakao, and E. Yano Relationship between major depression and high serum cholesterol in Japanese men Tohoku J. Exp. Med. 204 4 2004 273 287
29. T.C. Piermartiri, S. Vandresen-Filho, B. de Araujo Herculano, W.C. Martins, D. Dal'agnolo, E. Stroeh, C.L. Carqueja, C.R. Boeck, and C.I. Tasca Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake Neurotoxic. Res. 16 2 2009 106 115
30. T.C. Piermartiri, C.P. Figueiredo, D. Rial, F.S. Duarte, S.C. Bezerra, G. Mancini, A.F. de Bem, R.D. Prediger, and C.I. Tasca Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-beta(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage Exp. Neurol. 226 2 2010 274 284
31. R.D. Porsolt, A. Bertin, and M. Jalfre Behavioral despair in mice: a primary screening test for antidepressants Arch. Int. Pharmacodyn. Ther. 229 2 1977 327 336
32. S.G. Raja, and G.D. Dreyfus Statins: much more than just a lipid-lowering therapy Indian Heart J. 56 3 2004 204 209
33. M.S. Sadaghiani, M. Javadi-Paydar, M.H. Gharedaghi, Y.Y. Fard, and A.R. Dehpour Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway Behav. Brain Res. 224 2 2011 336 343
34. M. Schachter Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update Fundam. Clin. Pharmacol. 19 1 2005 117 125
35. N. Schintu, L. Frau, M. Ibba, P. Caboni, A. Garau, E. Carboni, and A.R. Carta PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease Eur. J. Neurosci. 29 5 2009 954 963
36. F.J. Sim, J.K. Lang, T.A. Ali, N.S. Roy, G.E. Vates, W.H. Pilcher, and S.A. Goldman Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation Glia 56 9 2008 954 962
37. S. Sundararajan, J.L. Gamboa, N.A. Victor, E.W. Wanderi, W.D. Lust, and G.E. Landreth Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia Neuroscience 130 3 2005 685 696
38. S.J. Tsai Statins may enhance the proteolytic cleavage of proBDNF: implications for the treatment of depression Med. Hypotheses 68 6 2007 1296 1299
39. S. Tyrovolas, C. Lionis, A. Zeimbekis, V. Bountziouka, M. Micheli, A. Katsarou, N. Papairakleous, G. Metallinos, K. Makri, E. Polychronopoulos, and D.B. Panagiotakos Increased body mass and depressive symptomatology are associated with hypercholesterolemia, among elderly individuals; results from the MEDIS study Lipids Health Dis. 8 2009 10
40. F. Yildiz, B.F. Erden, G. Ulak, T. Utkan, and N. Gacar Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats Psychopharmacology (Berl) 149 1 2000 41 44
41. Y. Young-Xu, K.A. Chan, J.K. Liao, S. Ravid, and C.M. Blatt Long-term statin use and psychological well-being J. Am. Coll. Cardiol. 42 4 2003 8
42. H. You, W. Lu, S. Zhao, Z. Hu, and J. Zhang The relationship between statins and depression: a review of the literature Exp. Opin. Pharmacother. 14 11 2013 1467 1476.